ArticleEuropean journal of heart failure2021
Impact of mitral regurgitation in patients with worsening heart failure: insights from BIOSTAT-CHF.
Article in European journal of heart failure, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 59 citations in OpenAlex.
- Prevalence and Risk Factors of Readmission Among Patients with Cardiovascular Diseases in Africa: A Systematic Review.Journal of epidemiology and global health · 2026Pooled it
- European Journal of Heart Failure expert consensus statement on transcatheter treatment of mitral regurgitation in heart failure.European journal of heart failure · 2025Guideline
- Association Between Preoperative Gait Speed and Mortality in Patients with Transcatheter Edge-to-Edge Mitral Repair.Diseases (Basel, Switzerland) · 2026Article
- Factors associated with the development of severe mitral regurgitation in patients with heart failure.Open heart · 2026Article
- Predicting heart failure decompensation: focus on non-invasive monitoring.Cardiology journal · 2026Review
- Epidemiology, pathophysiology, diagnosis and management of atrial functional mitral regurgitation: An expert opinion paper.ESC heart failure · 2025Review
- Emerging biomarkers for vascular remodeling in volume and pressure overload in a cardiology cohort.International journal of cardiology. Heart & vasculature · 2025Article
- Functional Mitral Regurgitation in the Transcatheter Era: Diagnostic and Therapeutic Pathways.Journal of personalized medicine · 2025Review
- Registries on transcatheter edge-to-edge repair in heart failure: Current evidence and future perspectives.European journal of heart failure · 2025Review
- Impact of heart failure severity on the mortality benefit of mitral transcatheter edge-to-edge valve repair.Clinical research in cardiology : official journal of the German Cardiac Society · 2025Article
- Worsening heart failure: progress, pitfalls, and perspectives.Heart failure reviews · 2025Review
- Development and validation of an early prediction model for cardiac death risk in patients with light chain amyloidosis: a multicenter study.Cardio-oncology (London, England) · 2025Article
- Assessing the impact of transcatheter edge-to-edge repair on reverse remodeling in secondary mitral regurgitation: a systematic review and meta-analysis.Frontiers in cardiovascular medicine · 2025Review
- A Comprehensive Geriatric Workup and Frailty Assessment in Older Patients with Severe Aortic Stenosis.Journal of clinical medicine · 2024Review
- Guideline-directed medical therapy assessment in heart failure patients undergoing percutaneous mitral valve repair.ESC heart failure · 2024Article
- Article
- Non-revascularized chronic total occlusions impact on substrate and post-ablation results in drug-refractory electrical storm.Frontiers in cardiovascular medicine · 2023Article
- Heart failure: an update from the last years and a look at the near future.ESC heart failure · 2022Review
- Clinical implications of left atrial changes after optimization of medical therapy in patients with heart failure.European journal of heart failure · 2022Article
- Clinical impact of changes in mitral regurgitation severity after medical therapy optimization in heart failure.Clinical research in cardiology : official journal of the German Cardiac Society · 2022Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
16 authors at 10 institutions in 8 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsFew data regarding the prevalence and prognostic impact of mitral regurgitation (MR) in patients with worsening chronic or new-onset acute heart failure (HF) are available. We investigated the role of MR in the BIOlogy Study to TAilored Treatment in Chronic Heart Failure (BIOSTAT-CHF). METHODS AND
resultsWe performed a retrospective post-hoc analysis including patients from both the index and validation BIOSTAT-CHF cohorts with data regarding MR status. The primary endpoint was a composite of all-cause death or HF hospitalization. Among 4023 patients included, 1653 patients (41.1%) had moderate-severe MR. Compared to others, patients with moderate-severe MR were more likely to have atrial fibrillation and chronic kidney disease and had larger left ventricular (LV) dimensions, lower LV ejection fraction (LVEF), worse quality of life, and higher plasma concentrations of N-terminal pro-B-type natriuretic peptide (NT-proBNP). A primary outcome event occurred in 697 patients with, compared to 836 patients without, moderate-severe MR [Kaplan-Meier 2-year estimate: 42.2% vs. 35.3%; hazard ratio (HR) 1.28; 95% confidence interval (CI) 1.16-1.41; log-rank P < 0.0001]. The association between MR and the primary endpoint remained significant after adjusting for baseline variables and the previously validated BIOSTAT-CHF risk score (adjusted HR 1.11; 95% CI 1.00-1.23; P = 0.041). Subgroup analyses showed a numerically larger impact of MR on the primary endpoint in patients with lower LVEF, larger LV end-diastolic diameter, and higher plasma NT-proBNP.
conclusionsModerate-severe MR is common in patients with worsening chronic or new-onset acute HF and is strongly associated with outcome, independently of other features related to HF severity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.